STUDY DESIGN: On gestational day (GD) 12, mini-osmotic pumps infusing sFlt-1 and sEng were placed into rats to induce HELLP. A subset of HELLP and NP rats underwent bilateral renal ischemiareperfusion surgery for 45 minutes on GD18 to create AKI. After rats had recovered, all rats were placed in metabolic cages for 24hrs. Mean arterial pressure was measured on GD19 followed by Evan's blue infusion to assess blood brain barrier permeability, or tissue collection and euthanization. RESULTS: During pregnancy HELLP+AKI rats had a significant decrease in urine output compared to NP rats (1.4+0.28 vs. 0.48+ 0.12mL/hr; p¼0.01). MAP was significantly increased in HELLP rats (p<0.0001) and HELLP+AKI rats (p¼0.03) compared to NP rats. Kidney weight was also significantly increased in NP+AKI compared to NP rats (p¼0.005) and in HELLP+AKI compared to HELLP rats (p¼0.003). Urine creatinine levels were significantly lower in all groups of rats compared to NP rats (p¼0.01). NP pups were significantly larger compared to HELLP (p¼0.006), NP+AKI (p¼0.0002) and HELLP+AKI (p¼0.0005) pups. Rats with HELLP had increased blood brain barrier permeability in the brainstem/ cerebellum compared to NP rats (p¼0.04). Similar results were seen in NP+AKI (p¼0.04) and HELLP+AKI (p¼0.01) rats compared to NP rats. Whole brain water weight was significantly increased in HELLP+AKI rats compared to NP rats (p¼0.03).
CONCLUSION:
The results from the current study suggest that AKI during pregnancy contributes to oliguria, hypertension, decreased urine creatinine, maternal brain injury and reduced pup size. In the setting of HELLP+AKI brain injury was worsened compared to rats with just AKI or HELLP syndrome. Studies are currently ongoing to examine the progression to chronic kidney disease and cognitive failure in rats with a history of sPE/HELLP with and without AKI during pregnancy. OBJECTIVE: Preeclampsia (PE) is characterized by new onset hypertension in association with elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and endothelin-1 (ET-1) levels. We and others have previously demonstrated that infusion of sFlt-1 into pregnant rodents causes hypertension, indicating an important role for sFlt-1 in mediating the pathophysiology of the disease. Currently there is no effective treatment for PE except for delivery of the fetal placental unit, making PE a leading cause for premature births worldwide. Administration of 17-hydroxyprogesterone caproate (17-OHPC) is used for prevention of recurrent preterm birth, but not for treatment of PE. This study was designed to test the hypothesis that 17-OHPC improves hypertension and ET-1 in response to sFlt-1 in pregnant rats. STUDY DESIGN: sFlt-1 was infused into normal pregnant (NP) Sprague-Dawley rats (3.7 mg$kg À1 $day À1 for 6 days, gestation days 13-19) in the presence or absence of 17-OHPC (3.32mg/kg) administered via intraperitoneal injection on gestational days 15 and 18. Mean arterial blood pressure (MAP), renal cortex endothelin-1 expression and Nitrate-Nitrite levels were measured on GD 19. RESULTS: Infusion of sFlt-1 into NP rats elevated mean arterial pressure (MAP) compared with control NP rats: 112+2 (n¼11) vs. 98+2 mmHg (n¼15, p<0.05). Administration of 17-OHPC attenuated this hypertension reducing MAP to 99+4 mmHg in sFlt-1 treated pregnant rats (n¼8). Importantly, renal cortex PPET-1 expression was elevated 3 fold in NP+sFlt-1 rats compare to NP rats, which decreased with 17-OHPC administration. Plasma nitrate-nitrite levels were 26 mM in NP rats (n¼6), 17 mM in NP+sFlt-1 (n¼4), which increased to 27 mM NP+sFlt-1+17OHPC (n¼5).
Neither pup nor placental weight was affected by sFlt-1 or 17-OHPC. CONCLUSION: Administration of 17-OHPC improves hypertension in response to elevated sFlt-1 during pregnancy and should be considered further in the management of PE.
445 Maternal cardiovascular hemodynamics in preeclampsia allows identification of patients with a more severe clinical phenotype 
OBJECTIVE:
The limitation of the current assertion of PE is that blood pressure is used to stratify the severity of illness, even when the hemodynamic of the phenotypes may differ. We sought to describe the clinical characteristics of patients with late-onset PE classified according to their hemodynamic profile. STUDY DESIGN: Prospective observational study in an obstetricreferral center in Cartagena, Colombia. Thirty pregnant women presenting with PE were recruited consecutively and maternal cardiovascular parameters were obtained through bioreactance using a noninvasive continuous cardiac output monitor. Patients were classified into two profiles: 1) PE with normal total peripheral resistance (TPR) (n ¼ 12) and 2) Hypodinamic profile, for those PE with high TPR (>1180 dyn*sec/cm 5 ) (n¼17). RESULTS: There were no significant differences in clinical characteristics between the study groups. Clinical and laboratory parameters such as SBP, DBP, platelets count, creatinine, LDH, AST, and ALT were also similar between groups (all p values, >0.05) (Table 1) . However, PE with high RPT had worse hemodynamic parameters than those with normal RPT: Significantly lower cardiac output, stroke volume, and oxygen delivery index compared to controls (all p values <0.05). Furthermore, PE with high RPT had a trend towards higher BNP and longer length of hospital stay, but also their newborns have significantly lower birthweight percentile (Figure 1 ). 
